Marker Therapeutics
MRKR
65 hedge funds and large institutions have $28.3M invested in Marker Therapeutics in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 8 closing their positions.
479% more call options, than puts
Call options by funds: $191K | Put options by funds: $33K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
0% more funds holding
Funds holding: 65 → 65 (0)
1.78% less ownership
Funds ownership: 33.79% → 32.01% (-1.8%)
27% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 22
36% less capital invested
Capital invested by funds: $44.5M → $28.3M (-$16.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$295K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$163K |
| 3 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
+$145K |
| 4 |
VWM
Vigilare Wealth Management
Scottsdale,
Arizona
|
+$91.9K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$461K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$403K |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$351K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$320K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$149K |
MRKR Hedge Fund Activity: Q1 2020 in Review
65 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q1 2020, worth a combined $28.3M — down 36% from $44.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new MRKR positions and 8 closed out — a net gain of 1 holder — while 16 added to existing stakes and 22 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $295K. The largest seller was Morgan Stanley, cutting an estimated $461K.
- 65 institutional investors held Marker Therapeutics (MRKR) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $28.3M of Marker Therapeutics stock for Q1 2020, down 36% quarter-over-quarter.
- 9 funds opened new Marker Therapeutics positions in Q1 2020 and 8 closed out, a net change of +1 holder.
- The largest Marker Therapeutics buyer in Q1 2020 was Renaissance Technologies, an estimated $295K added.
- The largest Marker Therapeutics seller in Q1 2020 was Morgan Stanley, an estimated $461K sold.
Based on aggregated 13F filings for Q1 2020.